Nascent Biotech
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Nascent Biotech generated cash of -$1,186,066, which is more than the previous year. Cash used in financing activities reached the amount of $1,386,000 last year. Net change in cash is therefore $199,934.
Cash Flow
| 2015 | -473.29K | -827.96K | 1.29M |
|---|---|---|---|
| 2016 | -170.42K | 0 | 636.2K |
| 2017 | -768.84K | 0 | 325.3K |
| 2018 | -1.22M | 0 | 1.21M |
| 2019 | -711.80K | 0 | 726.28K |
| 2020 | -554.32K | 0 | 426.07K |
| 2021 | -986.78K | 0 | 985K |
| 2022 | 413.47K | 0 | -320.5K |
| 2023 | -1.78M | 0 | 1.86M |
| 2024 | -1.18M | 0 | 1.38M |
NBIO Cash Flow Statement (2015 – 2024)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 172.18K | 94.41K | 1.43K | 3.21K | 131.47K | 116.99K | 129.80K | 573.35K | 107.57K | 113.83K |
Operating activities | ||||||||||
Net income | -2.08M | -2.80M | -470.39K | -958.76K | -4.00M | -1.36M | -2.22M | 1.13M | -4.15M | -2.15M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 377.90K | 1.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 882.09K | 756.32K | 116.08K | 785.85K | 1.10M | 208.43K | 149.43K | 118.33K | 3.78M | 119.31K |
| Deferred income tax benefit | 882.09K | 756.32K | 116.08K | 785.85K | 1.10M | 208.43K | 149.43K | 118.33K | 3.78M | 119.31K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 750K | -750K | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 260.96K | -245.51K | 167.06K | 230.40K | 327.02K | 322.26K | 0 | 0 | -4.67K | -625 |
Cash generated by operating activities | -1.18M | -1.78M | 413.47K | -986.78K | -554.32K | -711.80K | -1.22M | -768.84K | -170.42K | -473.29K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -827.96K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -827.96K |
Financing activities | ||||||||||
Common Stock Issued | 1.56M | 208K | 0 | 640K | 115K | 643K | 1.16M | 325.05K | 695K | 1.29M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 696.2K | 1.29M |
Repayments of term debt | 0 | 1.65M | -320.5K | -345K | -200K | 0 | 0 | 0 | -60K | 0 |
Cash used in financing activities | 1.38M | 1.86M | -320.5K | 985K | 426.07K | 726.28K | 1.21M | 325.3K | 636.2K | 1.29M |
Net Change In Cash | 199.93K | 77.77K | 92.97K | -1.78K | -128.25K | 14.47K | -12.81K | -443.54K | 465.78K | -6.26K |
Cash at end of period | 372.12K | 172.18K | 94.41K | 1.43K | 3.21K | 131.47K | 116.99K | 129.80K | 573.35K | 107.57K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |